Human M2e peptide immunogens
The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
1. A peptide immunogen consisting of the sequence of:
[Xaa 0 ] m -Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -[Xaa 6 ] p -
[Xaa 7 ] q -[Xaa 8 -[Xaa 0 ] m -Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -
[Xaa 6 ] p -[Xaa 7 ] q ] n
wherein, m, p and q are independently 0 or 1,
n is any number between 1 and 4,
Xaa 0 , Xaa 6 , Xaa 7 and Xaa 8 is independently any amino acid,
Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 is S-L-L-T-E.
2. The peptide immunogen of claim 1 , wherein Xaa 0 is C.
3. The peptide immunogen of claim 1 , wherein Xaa 6 is V or C.
4. The peptide immunogen of claim 1 , wherein Xaa 7 is E.
5. The peptide immunogen of claim 1 , wherein Xaa 8 is G or A.
6. The peptide immunogen of claim 1 , wherein said peptide is non-linear, and wherein said peptide is cyclic, and n is any number between 1 and 4.
7. The peptide immunogen of claim 1 , wherein said peptide is a Linear or cyclized peptide having the sequence SLLTEVGSLLTEV (SEQ ID NO: 320).